As you can see below, at the end of June 2024, Pfizer had US$69.9b of debt, up from US$65.7b a year ago. Click the image for ...

PFE's non-COVID drugs and potential contribution from new and newly acquired products have started to drive growth.

Pharmaceutical giant Pfizer ( PFE 2.73%) stands out in this context. The company currently offers a mouthwatering 5.7% ...

Pfizer's recent financial performance shows 14% YoY operational growth excluding COVID sales. Check out more on PFE stock ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

We recently compiled a list of the Jim Cramer’s Top 12 Must-Watch Stocks. In this article, we are going to take a look at ...

KP.2-adapted COVID-19 vaccine received FDA approval. Manufacturing Optimization Program aims to deliver $1.5b in savings by ...

In comparison, at its current levels of around $195, AbbVie stock trades at 18x expected 2024 earnings of $10.88 per share. This compares with the 12x average P/E multiple for ABBV seen over the last ...

New treatment builds on Pfizer’s migraine portfolio to further meet the needs of people living with this debilitating disease ...

Pfizer’s experimental cancer weight loss drug helped patients regain weight in a mid-stage study giving fresh promise for the ...

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Pfizer PFE in the ...

A mural honoring ancient and modern figures in medicine that has hung in the lobby of Pfizer’s original New York City ...